36BB
Structure of BA.4-S-RBD/Ab#10-M30W-S94M
Summary for 36BB
| Entry DOI | 10.2210/pdb36bb/pdb |
| EMDB information | 77348 |
| Descriptor | Ab#10-M30W-S94M heavy chain, Ab#10-M30W-S94M light chain, Spike protein (3 entities in total) |
| Functional Keywords | sars-cov-2, viral protein |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 3 |
| Total formula weight | 100217.78 |
| Authors | |
| Primary citation | Pallesen, J.,Du, J.,Wu, Y.,Ghosh, S.,Bayruns, K.,Sadeesh, R.,Weiner, D. Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants. Res Sq, 2026 Cited by PubMed Abstract: The ongoing evolution of SARS-CoV-2, particularly the emergence of Omicron subvariants, compromised the effectiveness of many therapeutic antibodies. In this study, we employed a structure-guided computational design strategy to systematically optimize the COV2-2196 antibody for improved neutralization of Omicron variants. Through iterative rounds of computational design and experimental validation, we identified key paratope mutations that restored and enhanced antibody binding and neutralization potency against resistant viral strains. Cryo-EM structural analysis revealed the molecular basis for these improvements, highlighting how targeted modifications can accommodate epitope changes introduced by viral evolution. Our approach demonstrates that effective antibody optimization can be achieved using accessible computational resources, providing a practical framework for rapid therapeutic development. These findings underscore the potential of structure-based design to address challenges posed by viral antigenic drift and support the development of broadly effective antibody therapeutics for emerging infectious diseases. PubMed: 42396495DOI: 10.21203/rs.3.rs-9917568/v1 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.6 Å) |
Structure validation
Download full validation report






